Devices & Diagnostics, Health IT, Startups

Analyst sees Medtronic’s new business strategy as indicator of ‘challenging outlook for medtech’

Not everyone’s buying Medtronic‘s (MDT) new do. On the heels of Medtronic’s Q1 results report, […]

Not everyone’s buying Medtronic‘s (MDT) new do.

On the heels of Medtronic’s Q1 results report, Deutsche Bank analyst Greg Poole had this to say:

. . . of greater interest to us was management’s commentary on the quarterly call regarding its strategy of transforming from a device provider to a global medical technology solutions partner. While we wouldn’t disagree that this is a good strategic move, albeit not one without risks, we see it as further evidence of the evolving landscape and more challenging outlook for MedTech.

Medtronic acquired Cardiocom last week, entering into the disease management field.

For more on the financial impact of this news and to see the full comment, see Benzinga.

Shares0
Shares0